Inactief instrument

Andere talen Matinas BioPharma Holdings Inc Other OTC

Aandelen

US5768101058

slotkoers Other OTC Andere beurzen
- ^USD	-

24/06	Matinas Biopharma meldt succesvolle behandeling van patiënt met ledemaatbedreigende Mucor-infectie in haar orale Mat2203 Compassionate/Expanded Use Access-programma	CI
18/06	Transcript : Matinas BioPharma Holdings, Inc. - Special Call

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program	24/06
Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program	24/06
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin	13/06
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin	13/06
Matinas Biopharma Holdings, Inc.'s Oral MAT2203 Featured in Fireside Chat	13/06
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024	16/05
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024	16/05
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update	09/05
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting	07/05
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024	02/05
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	01/05
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	30/04
In Vivo Efficacy of Matinas BioPharma?s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	30/04
Matinas BioPharma Prices $10 Million Registered Direct Offering	03/04
Matinas BioPharma Prices $10 Million Registered Direct Offering	03/04
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	27/03
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	27/03
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate, Expanded Use Access Program Achieve Complete Clinical Response	25/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Matinas BioPharma Holdings Inc Other OTC

Aandelen

US5768101058

Andere talen

Filters